人凝血酶原复合物分离纯化工艺的研究进展  

Advance in Fractionation and Purification for Human Prothrombin Complex Concentrates

作　　者：邱家山[1] 徐琦[1] 方为茂[1] 钟本和[1] 

机构地区：[1]四川大学化工学院,成都610065

出　　处：《生物技术通报》2006年第2期17-20,24,共5页Biotechnology Bulletin

摘　　要：人凝血酶原复合物(PCC)为人血浆中微量蛋白组份,其浓缩制剂由凝血因子II、VII、IX、X组成,在临床上具有治疗乙型血友病等疾病的确切疗效。本文综述了近来PCC及FIX浓缩制剂分离纯化工艺的研究进展及结合蛋白新型分离纯化技术的发展情况,讨论了该产品制备新工艺的开发方向。Prothrombin Complex Concentrates （PCC） are minim fraction in human plasma. It contains factor Ⅱ, factor Ⅶ, factor Ⅸ, factor Ⅺ. PCC are currently licensed for the treatment of Hemophilia B and of the deficiencies of the Vitamin K dependent coagulation factor. This paper has resulted in the development of the fractiona- tion and purification for PCC and highly purified FIX. The new preparation of PCC and FIX are presented by the development of new technology about proteins fractionation and purification.

关 键 词：人凝血酶原复合物 分离纯化 血浆蛋白 

分 类 号：TQ464.8[化学工程—制药化工]